Rukobia Approved for Heavily Treatment-Experienced HIV Patients With Limited Options
The FDA has approved Rukobia (fostemsavir; ViiV Healthcare), in combination with other antiretrovirals, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.